Quinbolone was never produced in the US and has only been marketed in Italy under the trade name Anabolicum Vistar by Parke Davis. Quinbolone’s structure is very similar to methandrostenolone and boldenone. It is taken orally, but is not C-17 alpha alkylated; instead it contains a cyclopentenyl ether, making it more similar to equipoise than to dianabol. This eliminates the worry of liver toxicity; however, quinbolone is not very active orally because of the lack of C-17 alkylation. Quinbolone has a very short half-life and a probability of aromatization to estrogen and moderate affinity for the androgen receptor. This steroid can also be converted to potent 5-alpha reduced metabolites. There is some disagreement over whether the ether is removed through metabolism or not. If the ether is not removed, then the binding affinity for this steroid is likely to be reduced. Most of what can be said for boldenone applies to quinbolone except that quinbolone’s half-life is very short and the gut destroys much of it before getting into circulation. The anabolic to androgenic ratio shows this steroid to be fairly weak compared to methyltestosterone orally.
Adapted with permission from Seth Robert’s Anabolic Pharmacology, all rights reserved.